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Abstract 
Dendritic cells (DCs) use effective mechanisms to combat antigens and to bring about adaptive immune 
responses through their ability to stimulate nӓive T cells. At present, four major cell types are categorised as DCs: 
Classical or conventional (cDCs), Plasmacytoid (pDCs), Langerhans cells (LCs), and monocyte-derived DCs (Mo-
DCs). It was suggested that pDCs, CD1c+ DCs and CD141+ DCs in humans are equivalent to mouse pDCs, 
CD11b+ DCs and CD8α+ DCs, respectively. Human CD141+ DCs compared to mouse CD8α+ DCs have 
remarkable functional and transcriptomic similarities. Characteristic markers, transcription factors, toll-like 
receptors, T helpers (Th) polarisation, cytokines, etc. of DCs are discussed in this review. Major histocompatibility 
complex (MHC) I and II antigen presentation, cross-presentation and Th polarisation are defined, and the dual 
role of DCs in the tumour is discussed. Human DCs are the main immune cells that orchestrate the immune 
response in the tumour microenvironment. 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Since their discovery by Ralph Steinman and 
Zanvil Cohn in 1973, much information about dendritic 
cells (DCs) has accumulated in the literature [1]. In 
2011 Ralph Steinman was awarded the Nobel Prize in 
Physiology or Medicine for his contribution in the 
investigation of dendritic cells and of their importance 
in initiating the adaptive immune response [2]. The 
unique function of DCs is their ability to stimulate 
nӓive T cells and to be a bridge between innate and 
adaptive immunity [3]. DCs have highly effective 
mechanisms to detect and capture antigens and to 
bring about of adaptive immune responses. Several 
recent reviews have highlighted similarities and 
differences in human and mouse DCs [3], [4], [5], [6]. 
DCs continuously interact with T cells even in 
the absence of infection. Moreover, DCs presenting 
self-antigens also interact with T cells in the steady-
state [7]. Thus, DCs enforce peripheral T cell 
tolerance by the continuous presentation of self- or 
innocuous antigens to T cells in the absence of co-
stimulation or activating cytokines. DCs mediate 
tolerance and silencing, thus preventing unwanted 
immune reactions to self and environmental antigens. 
This “tolerogenic” role of DCs is extensively studied in 
the light of their therapeutic application [2].  
In the current review, we present the human 
DC subsets and some mouse DCs that were thought 
to be equivalent to human ones and focus on recent 
advances in human DC development and function. 
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DC development 
  
In mice, the common myeloid progenitor or 
macrophage / DC progenitor (MDP) that gives rise to 
monocytes and macrophages on the one hand and 
the common DC progenitor (CDP) on the other is 
localised in bone marrow (BM). The CDPs in BM 
develop first into pre-DCs (entering blood) that in turn 
gives rise to classical or conventional DCs (cDCs) and 
into plasmacytoid DCs (pDCs) [8], [9]. Recent studies 
showed that cDCs are an independent haematopoietic 
lineage [9]. The cDC-restricted progenitor is registered 
in the spleen [10], and Liu et al., defined similar pre-
DC populations in the BM and other tissues. In the BM 
CDPs change to pre-DC, that move using blood flow 
to peripheral lymph nodes (LN) and to non-lymphoid 
tissues (NLT), where they differentiate terminally into 
cDC subsets (CD11b
+
 DC tissues, CD4
+
CD11b
+
 DCs 
and CD8
+ 
/ CD103
+
 DCs) [10]. In the periphery, cDCs 
live briefly and are very plastic, which allows a rapid 
function in response to antigens [8]. 
Interferon regulatory factor 8 (IRF8) is a key 
transcription factor important for the development of 
CD8α
+
 cDCs and CD103
+
 DCs. Basic leucine zipper 
transcriptional factor ATF-like 3 (BATF3), Id2-GFP 
and the nuclear factor interleukin 3 (NFIL3) initiate the 
development of CD8α
+
 cDCs as well as of CD103
+
 
DCs [11], [12], [13].  
In mice, pDCs develop in the BM from 
multiple progenitor types such as MDP, committed 
lymphoid (CLP) or myeloid (CMP) progenitors [14]. 
Pre-PDCs lose their potential to give rise to other cell 
types (a process called commitment) when maturing 
[10], [15], [16]. The earliest progenitors suck as CMPs 
give rise to erythrocytes, granulocytes, 
megakaryocytes, monocytes, macrophages, myeloid 
dendritic cells (mDCs) and pDCs [16]. Moreover, 
pDCs and cDCs developed from CDP or pre-DCs in 
murine BM, and express FMS-like tyrosine kinase 3-
ligand cytokine receptor FLT3 (CD135) triggered by its 
ligand FLT3L [17], [18] as well as by several 
transcription factors such as PU.1 and IRF8 [8]. CDP 
also express macrophage colony-stimulating factor 
receptor (M-CSFR, CD115) and granulocyte-
macrophage colony-stimulating factor receptor (GM-
CSFR) [19], [20], and low levels of stem cell factor 
receptor (c-KIT; CD117) [14], [21], [22]. The 
development proceeds through immature pDCs in the 
BM to mature pDCs in blood [22]. 
In humans, the equivalents of mouse CMPs, 
CDPs and even pre-DCs are as yet undefined [23]. 
Human gene expression studies reveal that DCs form 
a separate cluster from monocytes and macrophages 
[24], a fact that has also been confirmed in mice [9]. 
Moreover, in inflammation monocyte-derived dendritic 
cells (Mo-DCs) were shown to arise from monocytes 
[25]. 
Because of their limited availability, human 
DC subsets have been studied mainly in culture. 
Commonly, the generation of interstitial DCs and LCs 
has been achieved in culture with CD34
+
 
hematopoietic progenitor cells (HPCs) with GM-CSF 
and tumour necrosis factor-alpha (TNFα) [26], [27] 
with or without IL4 producing Mo-DCs, and that are 
distinct from DCs developed from CDP [28]. Cells that 
are developed from whole BM in vitro with FTL3L 
have been used to study cross-presentation [29], [30]. 
It is established that in CD34
+
 HPCs GM-CSF / TNF-
α-driven culture system, BDCA3
+
 expression is found 
on CD14
+
-derived interstitial DCs. The addition of 
TGFβ enhances BDCA3 expression on CD14
+
 DCs 
(manipulated differentiation towards LCs), whereas 
IL4 enhances BDCA-3 expression in both CD14
+
 DCs 
and CD1a
+
 DCs (interstitial DC lineage) [26], [31]. 
Moreover, pDCs, CD1c
+
 DCs and CD141
+
 DCs can 
be derived in vitro by culturing CD34
+
 HPCs FTL3-L 
[32]. Identification of early DC precursors in human 
blood is difficult because all human CD34+ HPC 
precursors express the DCs activation marker MHC 
class II antigen. It is reported that human cDCs 
proliferate in blood or NLT [3], while the pDCs fully 
develop in BM and then leave it [33]. 
Human DCs arise from BM precursors such 
as granulocyte-macrophage DC (progenitors 
producing granulocytes, macrophages and DCs), and 
from macrophage-DC progenitors (producing 
macrophages and DCs), and MDP-derived common 
DC progenitors restricted to BM (producing cDCs and 
pDCs). Similarly, to MDPss, CDPs highly express M-
CSFR and FTL3R, and low levels of c-KIT, like in 
mice. CDPs are the precursors of both pre-pDCs and 
pre-cDCs, cells that are not fully mature. The 
maturation of pDCs is completed in the BM, and cDCs 
differentiate in tissues [34], [35]. 
The common monocyte progenitor through 
GMP gives rise to blood CD16
+
 and CD14
+
 
monocytes. The three types of DC, namely cDC1 
(CD141
+
), cDC2 (CD1c
+
) and pDCs (CD303
+
) develop 
therefrom pre-DCs [3], [36], [37]. Differentiated DC 
subsets and monocytes circulate in peripheral blood 
and can be found in lymphoid tissue as resident cells. 
In the skin, CD14
+
 Mo-DCs, cDC1, cDC2, 
macrophages and LCs (latter both derived from fetal 
Yolk sac/liver progenitors) can be detected. 
The genetic control of DC lineage achieved by 
distinct transcription factors, particular pattern 
recognition receptors that lead to the production of 
specialised secretory products. The devеlopment of 
cDC1 requires BATF3 and IRF8. The development of 
cDC2 is dependent on IRF4 and Kruppel-like factor 4 
(KLF4). The factors ID2 BATF3, and BCL6, 
associated with cDC development, are expressed at 
low levels in CDPs. Therefore, the induction of pDC or 
cDC development deposed on transcription factor 
expression on CDPs [35].  
The origin of pDCs relies on runt-related 
transcription factor 2 (RUNX2), classic I basic helix 
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loop helix (bHLH) factors, ZBTB-46, BCL11A, IRF7 
and IRF8 [14], [35]. One key transcription factor for 
the development of pDCs is E2-2 [11]. E2-2 regulates 
a large pDC gene program, which in turn regulates 
other key transcription factors for pDC development 
such as IRF8 and when expressed, it unlocks pDCs 
differentiation. The loss of E2-2 from mature pDCs 
converts their phenotype and function into cDC-like 
phenotype [38]. 
LCs originate under the control of RUNX3 and 
ID2 and need IL34 and TGFβ for their development 
[23], [35].  
 
Figure 1: Development of human DCs 
 
 
DC subsets 
 
There is a great confusion in literature 
concerning the designation of “myeloid” or ‘classical 
type I DCs (cDC1s)’ and type II ‘cDC2s’. Some 
investigators use CD8α
-
 CD4
+ 
CD205 / DEC205
-
 
CX3CR1
-
 CD11b
+
) for type 1 cDCs and CD8α
+
 CD4
-
 
CD11b
-
 CD205 / DEC205
+
 CX3CR1
+
 and C type lectin 
domain family 9 member A (CLEC9A)
+
 for type 2 
cDCs in mice [39?], [40], [41]. Moreover, CD1c / 
BDCA1
+
CD11c 
hi
CD123
-
 are named as mDC1, and 
CD141/BDCA-3+CD11c
lo
 are named as mDC2 in 
humans [42], [43]. On the contrary, other investigators 
use the term of cDC1 for CD8α
+
 or CD103
+
 DCs and 
cDC2 for CD11b
+
 DCs in mouse [44] and CD1c
+
 
(BDCA1
+
) for cDC2 and CD141
+ 
/ BDCA3
+
 for cDC1 
type in humans [37], [45]. 
Boltjes and van Wijk use the signature of 
CD1c
+
 and CD141
+
 DCs without determination of DCs 
type I or II for human DCs (3). Similarly, Collin et al., 
applied CD1c
+
 (Clec7A
+
 Clec6A
+
) and CD141
+
 
(Clec9A
+
 XCR1
+
) as major markers for human cDC 
types, and CD11b
+
 (tissues) and CD4
+
CD11b
+
 
endothelial cell-selective adhesion molecule (ESAM)
+
 
(lymphoid) and CD103
+
 (tissues), CD8α
+
 (lymphoid) 
Clec9A
+
 XCR1
+
 Langerin
+
 for mouse cDCs [37]. 
In their excellent review, Reynolds and 
Haniffa concluded [45] that mouse DCs expressing 
CD8α in the spleen and CD103 in NLT that are 
equivalent to human CD141 (thrombomodulin, BDCA-
3) DCs [46], [47], [48] are type 1 cDC. The type 2 cDC 
phenotype in mice are LIN
-
MHC I 
hi
 CD11c
+
 CD11b
+
, 
and this fraction also includes Mo-DCs and 
macrophages [25]. Therefore, mouse CD11b
+
 DCs 
and human CD1c
+
 DCs have been regarded as type 
cDC2 [45]. We also accept their definition of cDC1 
and cDC2. 
 
In Mice 
All DC subsets in mice have corresponding 
human counterparts. Murine cDCs or mDCs have 
been traditionally categorised into two distinct 
subsets: the ‘cDC1s’ for CD8α
+
 and CD103
+
 (tissues) 
DCs and cDC2s for CD11b
+
 DCs and CD172a
+
 DCs 
that lack CD8α marker (49). The third type of murine 
DCs is pDC, which retains their original name [40]. 
Both subpopulations can be found in LT, including 
spleen, LNs, BM, and NLT [13], [49]. 
Table 1: TLR expression in mouse DCs 
  cDC1  cDC2  pDC 
Phenotype NLT: CD8α
+
, CD11c
+
, 
MHC II
+
, CD103
+
, 
CLEC9A(DVGR)
+
, 
XCR1
+
, CD11b
-
 LT: 
CD8α
+
, MHC II
+
, 
CLEC9A
+
, XCR1
+
, 
CD205
- 
/ DEc205
+
, 
SIRPa (CD172a)
-
, 
CD11b
-
, CD4
-
 
 NLT: CD11b
+
, 
CD103-, MHC 
II+, XCR1
+
 LT: 
CD11b
+
, CD4
+
, 
CD8α
-
, SIRPa 
(CD172a)
+
, 
CD11c
+
 
 LT: CD11c
+
, 
MHC II
+
, CD317 
(BST2)
+
, Siglec 
H
+
, 
CD45R(B220)
+
, 
CD11b
-
, Ly-6C
+
 
TF TRF8, BATF3, ID2, 
Bcl6 
 TRF4, Notch2, 
Klf4 
 IRF8, E2-2, 
RUNX1, Bcl11a 
Location LT, NLT  LT, NLT  LT, NLT, BM 
TLRs TLR3 (TLR6, TLR8, 
TLR1, TLR2, TLR4) 
(TLR4 stimulates Th1 
immune response of 
IL12) 
 TLR8 (TLR (7)9) 
(TLR2 
stimulates Th2 
responses) 
 TLR7 (4,8) 
(TLR1,2) TLR9 
Cytokines TGFβ (induction of 
Treg) 
    
T-cell 
interactions 
CD8
+
T cell responses 
cross presentation 
with MHC class I 
molecules; Ag and 
immune complexes 
 Th2, Th17 
(allergies), 
(fungal) 
presentation of 
Ags with MHC 
class II 
molecules 
 CD4
+
Th2 - ? 
and CD8
+
Th1 
Biological 
roles 
Cross presentation - 
CD8
+
T cell response 
 CD4
+
T cells 
priming 
 Anti-viral 
response high 
production of 
IFNα / β, 
antiviral 
response 
 
CD8α
+
 and CD103
+ 
cDC1s. The CD8α
+
 cDCs 
have been found in murine lymphoid organs. An 
alogous DC population exists in NLT, and these cells 
express CD103 integrin marker (αεβ7). CD8α
+
 and 
CD103
+
 cDC1s are the best-characterised cDC 
subsets, conserved through evolution, and the 
chemokine receptor XCR1 (important for cross-
presentation) was identified first on these DCs [46]. 
CD8α
+
 cDCs are highly efficient in cross-presentation 
of exogenous antigens on MHC-I molecules to CD8
+
 T 
cells in CD1d context, a fact that is critical for 
immunity against viruses and bacteria [46] and in 
antitumor immunity [23]. Therefore, CD8α
+
 cDCs can 
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activate and polarise invariant natural killer T-cells 
towards the production of T helper 1 (Th1) and Th2 
cytokines and CD8α
+
 cDCs secrete IL12p70 [50], [51]. 
Skin-derived CD103
+
 cDCs also have cross-
presentation activity using MHC class I molecules to 
present antigens to CD8
+
 T lymphocytes [13].  
The phenotype of CD8α
+
 cDCs in LT has 
been delineated by the expression of CD11c
hi
, MHC 
class II
hi
, XCR1
+
, CLEC9A
+
, CD8α
+
, CD4
-
, CD205 
(DEC205)
+
 and that of CD103
+
 DCs in NLT 
(analogous to CD8α
+ 
in peripheral tissues) – by 
CD11c
hi
, MHC class II
hi
, XCR1
+
, CLEC9A
+
, CD8α
+
,
 
CD4
-
 CD11b
-
 and CD103
+
 [52]. 
CD11b
+
 DCs and CD172a
+
 DCs (cDC2s). A 
second and largely complementary DC subset can be 
distinguished in lymphoid organs by the expression of 
CD4 [12]. CD4
+
 CD11b
+
DCs cDC2 are considered to 
be poor cross-presenters in vivo but are more efficient 
while endogenous cytosolic antigens are presented on 
MHC class II to CD4
+
 T cells [53]. Moreover, CD4 is 
not expressed on the complementary peripheral 
subset (in NLT), which can be instead identified by the 
expression of CD11b. CD11b
+
 DCs are mostly defined 
by the absence of activities associated with CD8α
+
 
DCs [41]. They are inefficient at cross-presenting 
antigens and do not produce IL12. In contrast to 
CD8α
+
 DCs, CD11b
+
 DCs are superior in the induction 
of CD4
+
 T cell immune response because of their 
prominent expression of MHC class II machinery [13], 
[53], [54]. 
CD11b
+
 DCs prevail in lymphoid organs 
except for the thymus. They can also be detected in 
NLT. In the spleen DCs can be classified into three 
populations of resident cDCs: CD8α
+
 DCs, endothelial 
cell-selective adhesion molecule (ESAM)
hi
 CD11b
+
 
cDCs and ESAM
lo
 CD11b
+
 cDCs [23], [54]. Both 
CD11b+ cDCs in NLT and LT-resident DCs are 
occupied in the antigen presentation in MHC II-
restricted manner [52], [53]. 
Table 2: TLR expression in human DCs 
  cDC1 cDC2 pDC 
Phenotype Blood: CD141
+
(BDCA-3)
+
; 
LT: HLA-DR
+
, CLEC9a
+
, 
αCR1+, CD11c
+
, CD11b
-
, 
CD123
-
 
Blood – LT: 
CD1c(BDCA-1)
+
, HLA-
DR
+
, CD11b
+
, CD11c
+
, 
SIRPa(CD172a)
+
 
Blood: HLA-DR
+
, CD303 
(BDCA-2)
+
, CD304 
(BDCA-4)
+
, CD123 (IL-
3R)
++
, CD85g (IαT7)
+
, 
CD11c
-
 
TF IRF8, BATF3, ID2, Bcl6 TRF4, Klf4 IRF8, E2-2, RUNX2, 
Bcl11a, IRF7, bHLH 
Location Blood, LT, NLT Blood, LT, NLT Blood, LT 
TLRs TLR3 (TLR1, TLR2, TLR4), 
TLR5,6,8,10 
TLR8 (TLR7,9) 
TLR4 
TLR7, 9 (endosomes) 
(TLR1,6,10 low) 
facilitated IFN type I 
expression 
Cytokines   IFN α (TLR7/9) 
IFN III 
T-cell interactions CD8
+
T cell responses cross 
presentation with cellular Ags 
and immune complexes Th1 
Th2(allergies), (Th17 
fungal) 
CD4
+
Th2 
CD8
+
Th1 
Granzime B secretion 
Biological roles Anti-tumor, 
Anti-viral 
CD8
+
Th1 (IL-12) 
Regulation of immune 
responses; 
Anti-parasites, anti-
bacterial 
Anti-viral, 
Anti-fungal, 
Anti-tumor 
 
Conceivably, CD11b
+
ESAM
hi
 cells are also 
CD11c
hi
MHC class II
hi
, CX3CR1
low
, CD11b
+
 and 
ESAM
hi
 and are associated with CD4
+
 DC responses, 
while CD11b
+
ESAM
lo
 cDCs are CD11c
hi
MHC class 
II
hi
, CD103
-
, CD11b
+
 and CD24
-
 and produce 
inflammatory cytokines such as IL6 [55] and IL23 [3] 
upon toll-like receptor (TLR) triggering [40], [54]. 
CD11b
+
 DCs secrete also pro-inflammatory 
chemokines CCL3, CCL4 and CCL5 after TLR 
stimulation [56]. The two DCs types are NOTCH2-
dependent [54], and the latter type is also IRF4-
dependent [31]. 
 
In Humans 
Historically, human DC subsets have been 
defined concerning some phenotypic markers and 
anatomic location. Human DCs express high levels of 
MHC class II (HLA-DR) and CD45
+
 and lack typical 
lineage markers CD3 (T-cell), CD19 / 20 (B-cell) and 
CD56 (natural killer cell). The classical description of 
human DCs is HLA-DR
+
 lineage
-
 including myeloid 
and plasmacytoid subsets [37], [57].  
Human DCs consist of heterogeneous with 
distinct functional specializations categorized into, 
blood and lymphoid organ-resident DCs comprising 
CD11c
-
 CD123
hi
 CD303 (BDCA2)
+
 CD304 (BDCA4)
+
 
or pDCs secreting type I IFN. The other subset in this 
category is mDC that has been further delineated into 
a CD141 (BDCA3)
hi
 CLEC9A
+
 or the major cross-
presenters to CD8 T cells [47] and CD1c (BDCA1)
+
 
population [57]. Secondly, migratory DCs also exist 
that reside in NLT and response to danger signals 
migrate to lymphoid organs. Three migratory DC 
subsets belonging to myeloid lineage and expressing 
CD11c have been described in NLT including the skin. 
These are epidermal LCs (langerin
+
 CD1a
hi
 DC-
SIGN
+
), interstitial (CD1a
+
 DC-SIGN
-
) and CD14
+
 
(CD1a
-
 DC-SIGN
+
) DCs [27]. The latter subset is 
linked to human monocyte / macrophage populations 
[27], [48], [58]. Additionally, BDCA3+ CLEC9A+ DCs, 
capable of cross-presentation and IFNλ production 
have been identified in the human dermis [48]. Finally, 
inflammatory DCs differentiate from peripheral blood 
monocytes [59]. 
Concerning anatomic location human DCs are 
blood DCs (pDCs and mDCs), and mDCs have been 
separated into two subsets, namely BDCA3 / CD141
+
 
DCs and BDCA1 / CD1c
+
 DCs [17]. These three DC 
populations are found in all lymphoid organs and are 
considered as resident DCs [47], [58], [60]. 
Conceivably, immature cDCs leave the BM, 
disseminate via blood to lymphoid organs and 
peripheral tissues, where they achieve resident and 
migratory phenotype [61]. The resident cDCs in 
lymphoid tissue stay in an immature state unless they 
get activation signals and become mature [62]. The 
migratory (mature) cDCs travel from the tissues to the 
LNs via afferent lymph and mature upon reaching 
regional LNs [63]. Migratory cDCs transport and also 
present peripheral self-antigens to induce T-cell 
tolerance [64]. 
 In skin, liver, lung and intestine two main 
populations of cDCs exist, namely CD1c
+
CD1a
+
 and 
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CD141
+
 CLEC9A
+
 DCs [48]. These DCs migrate to 
draining lymph nodes and are called migratory DCs 
with mature phenotype [58]. In human mucosa 
tissues, additional DC subsets: LCs and CD14
+ 
DCs in 
the skin and vaginal mucosa and CD103
-
 CD172a
+
 
DCs in the intestine [65]. 
Some of the used phenotypic markers for DC 
definition can be expressed on several cell types or 
can be changed upon activation [17]. For example, 
CD141 is also upregulated after activation on pDCs 
and on CD1c
+
 DCs (except on traditional cDC1s) [42]. 
Intermediate levels of CD141 / BDCA-3 
(thrombomodulin) are expressed on tissue CD14
+
 
DCs [66], [67]. BDCA3 is a cell surface 
transmembrane glycoprotein that is predominantly 
expressed on vascular endothelial cells and has anti-
coagulant activity and anti-inflammatory function [68]. 
Another example is the rapid down-regulation 
of the classical cDC1s marker CLEC9A (restricted to 
CD141
+
 DCs) during maturation [69]. Moreover, using 
the classical hallmark of DCs (dendritic morphology, 
migratory capacity and the ability to stimulate naïve T-
cells) one can distinguish DCs from macrophages and 
monocytes [17].  
Finally, transcriptomic studies are useful to 
confirm DC identity. Homology between human 
(XCR1
+
 CD141
+
) cDC1s and mouse (CD8α
+ 
/ 
CD103
+
) cDC1s is demonstrated by comparative 
transcriptomic, phenotype and functional analyses 
[45], [47], [48], [60]. It has been suggested that pDCs, 
CD1c
+
 DCs and CD141
+
 DCs represent distinct 
lineages and are equivalent to mouse DC subsets 
pDCs, CD11b
+
 DCs and CD8α
+
 DCs, respectively 
[48], [65]. The origin of CD141+ DCs is maintained by 
BATF3 transcription factor [70]. 
 
CD141
+
 BDCA3
+
  
The essential role of DCs in the induction and 
regulation of immune responses to pathogens, self-
antigens, and cancer has been well established [71]. 
The characterisation of human DC subsets is difficult 
because of their rarity, the lack of distinctive markers, 
and limited access to human tissues [47]. Human 
blood DCs comprise ~ 1% of circulating peripheral 
blood mononuclear cells defined as antigen-
presenting leukocytes that lack other leukocyte 
markers such as CD3, CD14, CD15, CD19, CD20 and 
CD56, and express high levels of MHC class II (HLA-
DR) molecules [17]. 
Gene -expression profiling and hierarchical 
clustering data have indicated that CD1c+ DCs and 
CD141+ DCs have a common origin and represent 
two different stages of a similar subset [72]. However, 
CD1c+ DCs and CD141+ DCs have unique gene -
expression profiles differentiating them from 
monocytes and mo-DCs [42], [72].  
Human CD141+ (thrombomodulin+) DCs 
comprise only ~ 0.03% of human peripheral blood 
mononuclear cells and 10% of human blood mDCs 
[42]. Moreover, CD141+ DCs are present at small 
numbers in tissues, and other cells also express this 
marker although at a low level (CD14+ DCs, CD1c+ 
DCs and monocytes) therefore, they are difficult to 
identify [47]. Their differentiation from CD1c+ DCs by 
flow cytometry has been made possible by the fact 
that CD141+ DCs express less CD11b and CD11c 
[37].  
An efficient protocol for the isolation of highly 
pure CD141+ and CD1c+ mDCs from leukapheresis 
products from normal and healthy volunteers has 
been reported [73]. In an extensive and excellent 
study [48] isolate human DC subsets from human 
blood and skin (from mammoplasty), lung and liver 
(from peritumoral tissue), tonsil and dermatopathic 
LNs (from tonsillectomy and LN diagnostic excision). 
DCs can be isolated by fluorescence-activated cell 
sorting (FACS) analysis and are studied by flow 
cytometry. FACS-purified dermal DCs are cultured 
with TLR ligands, and cytokine secretion of DCs has 
been studied. Cross-presentation and ELISpot assay 
have been done. By quantitative real-time polymerase 
chain reaction, the following genes have been 
examined: GAPDH, XCR1, TLR3, and CADM1, and 
the results suggest that CD141
hi
 DCs are functional 
homologs of mouse CD103
+
 DCs and that these are 
distinct from the major population of human CD1c
+
 
DCs and mouse CD11b
+
 DCs. 
The main characteristics of the human 
CD141
+
 DC subset have been a high expression of 
TLR3 (but not of TLR4, 5, or 7) and the production of 
IFNβ, CXCL10 and IL12p70. Another characteristic of 
this subset is the induction of superior Th1 response 
after activation with polyinosinic–polycytidylic acid 
(poly I:C) and the induction of Th2 response to a lower 
degree, therefore, CD141
+
 DCs are the major subset 
involved in the induction of CTL responses against 
tumours and viruses [31]. Detailed functional analyses 
of human CD141
+
 DCs with impact of their role in the 
induction of Th1 and Th2 immune responses, TLR 
stimulation, TNFλ production, MHC class I and class II 
antigen and MHC class I cross-presentation, cytokine 
production and their origin in culture by CD34
+
 HPCs 
has been reported [17], [23], [31], [74], [75], [75], [76], 
[77], [78]. 
It has been shown that HLA-DR
+ 
lineage
-
 cells 
in human blood and tissues comprised two fractions 
CD14
-
 and CD14
+
. The CD14
-
 fraction is further 
separated by CD141 and CD11c expression by flow 
cytometry. CD141
+
 cells in the blood have low CD11c 
expression, and in tissues, they are CD141
hi
 CD11c
lo 
[48]. CD14
+
 cells in tissues express CD141, but they 
correspond to CD14
+
 “interstitial type DCs” that do not 
have very potent allo-stimulatory or cross-presenting 
capacity [27], [79]. Tissue CD141
hi
 (isolated from 
human skin, liver and lung) and also blood CD141
+
 
show higher expression of the cross-presentation 
signature CLEC9A, TLR3, CADM1, and XCR1 
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(whereas CD14
+
 and CD1c
+
 express these at much 
lower levels) and consequently migrate in response to 
XCL1. CD141
hi
 DCs migrate in response to XCL1 and 
show the highest expression of Flt3 and CLEC9A in 
blood, skin and lung whereas CD14+ DCs intensely 
express M-CSFR and CX3CR1, markers associated 
with monocyte and macrophage lineages. 
CD1c
+
 DCs show lower expression of FLT3 
and CLEC9A and intermediate levels of M-CSFR and 
CX3CR1 than CD141
hi
 DCs [48]. Reynolds and 
Haniffa suppose that blood CD141
+
 DCs are the 
precursors of immature CD141
hi
 DCs, before to 
acquire CD1a, CD1c, activation antigens, and CCR7. 
Moreover, migrating CD141
hi
 DCs represent the CD1a 
and CD1c mature fraction [45], [48]. 
Human CD141
+
 DCs have been compared to 
mouse CD8α
+
 DCs, and remarkable functional or 
transcriptomic similarities have been established [24].  
Both subsets share the expression of 
CLEC9A [80], [81], NECL2 [71], [82] and of the 
chemokine receptor XCR-1 [46], and are extremely 
rare in blood but are present in the T cell areas of LT 
[82]. 
The recognition of pathogen-associated 
molecular patterns by DCs involves pattern 
recognition receptors and TLRs [73]. To date, 10 
TLRs (TLR1-10) have been identified [83]. Human 
CD141
+
 DCs have strong expression of TLR3 and do 
not express TLR4, -5, and -7 [47], [84]. Mouse CD8α
+
 
DCs also have high expression of TLR3 and lacked 
TLR7 and TLR10 [47]. However, unlike human 
CD141
+
 DCs, mouse CD8α
+
 DCs express TLR4 and 9 
[85]. Human CD141
+
 DCs express TLR10 (absent in 
mice) at higher levels than CD1c+ mDCs [84]. TLR10 
belongs to the TLR1 subfamily like TLR1, -2, and -6 
[73] and its function remains to be determined. 
The effect of pathogen-TLR recognition is the 
induction of cytokine and chemokine production [86]. 
Like human CD141
+
 DCs, mouse CD8α
+
 DCs trough 
high TLR expression produce IFN-β in response to 
poly I:C [87]. 
Mouse CD8α
+
 DCs produce IL12p70, and 
induce Th1 cytokines IL2 and IFNγ [47], [88]. Most 
importantly, human CD141
+
 DC and mouse CD8α
+
 
DCs have the cross-presenting capacity [45]. Both 
subtypes express high levels of MHC class I [53] that 
together with TLR3 and CLEC9A (sensors of necrotic 
cells) regulate cross-priming [89]. 
Despite their similarities, there are notable 
differences between human CD141
+
 DCs and mouse 
CD8α
+
 DCs. Murine cDC1 differentiation requires the 
expression of BATF3 and IRF8 [47], [60] that are not 
selectively expressed by CD141
+
 DC. Human DCs are 
isolated mainly from blood, while mouse DCs are 
generally isolated from spleen [45]. 
 
 
CD1c+ mDCs 
 
Human CD1c
+
 DCs are the major population 
of mDCs in blood, peripheral tissues (NLT) and LT 
[37]. CD1c
+
 DCs comprise about 1% of all 
mononuclear cells in blood [37]. In kidney tissue there 
are about four times more BDCA1
+
 (CD1c
+
) DCs than 
BDCA2
+
 (pDCs) [90]. Human CD1c
+
 DCs classified by 
45, as cDC2 phenotype are defined as lineage
-
 MHC 
class II
+
 (HLA-DR
+
) CD14
-
 CD16
-
 CD11c
+ 
CD1c
+
, a 
definition, they share with in vitro Mo-DCs [45]. 
Human peripheral blood and murine cDC2 additionally 
express CD11b, CX3CR1 and SIRPα (CD172) [91] 
similarly to Mo-DCs [45]. 
Human CD1c
+
 DCs are identified by the 
commercial antibody BDCA1 [42]. Human blood 
CD1a
+
CD11c
+
 cells express high CD1c (BDCA1) 
levels and can rapidly acquire an LC phenotype [92], 
[93]. It has been shown that blood BDCA1
+
 DCs 
treated with thymic stromal lymphopoietin (TSLP) and 
TGFβ induce expression of high numbers of LCs 
(CD1a
+
 CD207
+
) [94]. 
Human tissue CD1c
+
 DCs appeared to be 
more activated than blood CD1c
+
 DCs and express 
co-stimulatory molecules such as CD80, CD83, CD86, 
and CD40, they lose homing receptors CLA and 
CD62L, while preserving CCR7 responsible for tissue 
homing [37], [93]. CD1c
+
 DCs are also detected in T-
cell areas of LNs, tonsils and spleen [47], human 
kidneys [57], [90], skin [94], and lung [95]. 
The pathogenic role of CD1c
+
 DCs in human 
disease is not clear, but they have been found to 
accumulate in chronic kidney disease [57], atopic 
airway asthma and are reduced in number in non-
small cell lung cancer [95] and atopic disease [96]. 
CD1c
+
 DCs express a wide range of lectin receptors, 
TLRs (TLR2, TLR3, TLR4, TLR5, TLR7, TLR8) and 
other pattern recognition receptors [73], [97] that are 
necessary for antigen uptake, transport and 
presentation. 
Human and mouse cDC2 share a similar 
cytokine production profile, which includes 
IL6, IL23 and IL1β, TNFα, IL8 and IL10 [73], 
[79]. This cytokine profile implies a dual role of CD1c
+
 
DCs in Th1, Th2 and Th17 sensitisation. 
Using a new isolation protocol Hemont et al., 
studied human CD141
+
 and CD1c
+
 mDCs concerning 
their TLR expression pattern and TLR ligands that 
determine DCs cytokine and chemokine expression. 
The average value is 1084 ± 580 CD1c
+
 mDCs and 
169 ± 81 CD141
+
 mDCs / 1x10
6
 peripheral blood 
mononuclear cells [73]. CD1c
+
 mDCs from human 
peripheral blood, BM and tonsils, and LT cross-
present soluble antigens and prime CTLs, and are 
most potent human IL12 producing DCs as compared 
to CD141
+
 mDCs. CD1c
+
 mDCs perform best upon 
TLR4 and TLR8 stimulation, whereas CD141
+
 mDCs 
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require agonists of TLR3 and TLR8 [98]. It has been 
shown that the immune reaction against Escherichia 
coli and Gram-negative bacteria in humans is most 
efficient by Mo-DCs that phagocytised it and are the 
main producers of TNFα, IL8 and IL6. CD1c
+
 DCs 
phagocytise Escherichia coli to a lesser extent than 
Mo-DCs and are weaker producers of cytokines in 
response to TLR4 ligand whereas CD141
+
 DCs are 
not responsible for processing and presentation of 
bacterial antigens [99]. Moreover, CD1c
+
 DCs exhibit 
a tolerogenic phenotype by secreting a high level IL10 
and expressing CD25 and IDO molecules on their 
surface [99], [100], [101]. 
 
 
pDCs 
 
pDCs were described first in human LNs by 
Frederick Siegal et al., [102] and later in mice by 
Asselin-Paturel et al., [111]. Recently, pDCs have 
been regarded as a part of the DC family [100], but 
cells with pDC features have been known as T-cell 
associated plasma cells or as plasmacytoid T cells, or 
as natural interferon-producing cells for several 
decades [101]. These cells produce 200 to 1,000 
times more IFNα and IFNβ than other blood cells in 
response to viruses [102]. pDCs produce IFN type I 
after engagement of their TLRs, namely TLR7 and 
TLR9 of viruses or self-nucleic acids [103].  
The markers usually used to identify pDCs in 
mice are CD11c
+
, B220
+
, Ly6C
+
, bone marrow stromal 
antigen 2 (BST2) and sialic acid-binding 
immunoglobulin-like lectin H (SIGLEC-H)
+
 [52]. Mouse 
pDCs also express CD8α and like human pDCs 
express CD4 and MHC class II. Mouse pDCs also 
express the chemokine receptor 9 (CCR9), Ly49Q 
SCA1 [18]. 
 
Human pDCs 
In contrast to mouse pDCs that show 
intermediate levels of CD11c
+
 expression, human 
pDCs are CD11c
-
 [18]. BST2 is fairly expressed on 
pDCs and plasma cells in steady-state and upon 
activation has been found on many cell types [104]. 
The SIGLEC-H expression is mainly confined to pDCs 
[105]. In humans, the origin of pDCs is not well 
understood because of the lack of reliable markers, 
paucity of DCs in blood, and the limited access to 
human tissues [60]. The typical phenotype of human 
pDCs is LIN
-
 CD11c
-
 CD123 (IL-3Rα)
+
 [22]. It has 
been shown that CD141
+
 cDCs develop after culturing 
CD34
+
 HPCs with c-KIT, FLT3L, GM-CSF, and IL4 
[60], and after stromal cell addition to the former 
cocktail, pDCs develop [106]. Importantly, DCs that 
arise from stromal cell cultures resembled CD1c
+
 
cDCs, CD141
+
 cDCs and pDCs obtained from 
peripheral blood as determined by gene expression, 
surface phenotype, and cytokine production [14]. 
Stromal cell culture has been used to support the 
development of HPCs into three major human DC 
subsets, and into monocytes, granulocytes, NK and B 
cells [107].  
Genome-wide analysis reveals that the gene 
expression profile of pDCs is closer to that of cDCs 
than to lymphocytes or myeloid cells [24]. After 
stimulation human pDCs can differentiate into cDCs 
[108]. PDCs are distinct from cDCs and possess 
features of lymphocytes [14]. The morphology of 
pDCs in the steady-state is that of a secretory 
lymphocyte [108], and their circulation/localisation is 
different from that cDCs resembling that of 
lymphocytes – pDCs matured in BM and then 
circulate in the blood and are seeded in the secondary 
lymphoid organs and thymus [33], [61]. Concerning 
viability pDCs are long-lived, as compared to cDCs 
and finally, pDCs share some molecular features of B 
lymphocytes (expression of CD45RA, MHC class-II 
molecule and BDCA-2) [109], [110]. 
Immature or resting pDCs are round in shape 
and are named pre-pDCs [108] with low expression of 
MHC class II and low T cell co-stimulation [63]. In 
peripheral tissues, pDCs are very low in number [111]. 
By secreting IFN I, pDCs can influence innate (e.g.NK 
cells) or acquired (e.g. cDCs and B cells) immunity 
[101]. At the site of inflammation, pDCs achieve DC 
morphology, proliferate and reach draining LNs (100). 
Mature pDCs secrete IFN, acquire a dendritic 
morphology and show up-regulation of MHC and T-
cell co-stimulatory molecules [111]. Mature pDCs can 
present antigen via MHC I and MHC II to CD8
+
 T cells 
and CD4
+
 T cells, respectively [112]. It has been 
supposed that pDCs participated mainly in antigen 
presentation and immunomodulation at sites of 
inflammation rather than in antigen transport to 
draining LNs for T-cell priming [63]. 
 
 
DC MHC Class I and MHC Class II Antigen 
Presentation. Cross-presentation 
 
Endogenous MHC I antigen presentation 
MHC class I molecules are expressed on the 
plasma membrane of all nucleated cells and until 
recently were considered to present endogenous 
peptide-derived antigens from dead and dying cells 
and to preserve cognate T-cell epitopes [113]. The 
MHC class I molecule consist of two chains – a heavy 
chain and a light chain called β2-microglobulin. The 
genetic nucleotide polymorphisms of the heavy chain 
ensure plenty of peptide-binding regions for antigenic 
proteins [114]. 
Antigen presentation consists in two 
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processes: Firstly, capturing and processing of 
precursor polypeptides from the extracellular 
compartment, and second the resulting T-cell priming, 
proliferation and consequent cytokine secretion after 
the recognition of MHC-peptide complexes by T-cells 
[64].  
The classical MHC I presentation pathway 
consist of three steps. Endogenous peptides (with 
errors appearing during protein synthesis) are 
attached with ubiquitin to be degraded in the cytosol 
by the proteasome, a process called antigen 
processing [115]. Some of these degradation products 
are required for MHC I attachment and are therefore 
delivered to the endoplasmic reticulum by the 
transporter associated with antigen processing, and 
are loaded onto newly formed MHC class I molecules 
[116]. In the endoplasmic reticulum longer, peptides 
are additionally degraded (trimmed by ERAP – 
endoplasmic reticulum aminopeptidases) – via 
endoplasmic reticulum-associated degradation and 
loaded onto MHC I molecules [117]. This process is 
called antigen loading. MHC I-peptide complexes are 
then exported to the cell surface through the Golgi 
complex (along the secretory pathway) [113]: antigen 
transport. T-cells use their TCR to recognise antigenic 
peptides presented on MHC molecules on the surface 
of antigen-presenting cells. MHC class I molecules 
are recognised by CD8 T cells [118]. 
 
MHC I cross-presentation 
Cross-presentation is considered to be the 
presentation of acquired exogenous antigens on MHC 
class I molecules that prime CD8+ T cell responses 
[119]. Therefore, DCs have to be infected with a virus 
or take other exogenous antigens, to break foreign 
peptides through its mechanism of “endogenous 
antigen processing” and to present the exogenous 
antigens via MHC I pathway [119]. This mechanism of 
presentation of exogenous antigens by the machinery 
of endogenous antigen presentation via MHC I is 
termed cross-presentation [113]. Exogenous antigens 
are internalised through micro- or macropinocytosis, 
receptor-mediated endocytosis or phagocytosis. To be 
cross-presented, these antigens go through the same 
three steps that comprised the endogenous pathway i. 
e. processing, loading and transport [113]. 
Cross-presentation represents an important 
pathway for the initiation of immune responses 
against tumours and viruses. Efficient presentation of 
exogenous antigens is realised by some other cells 
such as macrophages, B lymphocytes, liver sinusoidal 
endothelial cells, neutrophils and DCs [120]. B 
lymphocytes load antigens on MHC I and MHC II 
molecules but are less efficient presenters than DCs 
[121]. Neutrophils can cross-prime CD8+ T cells by 
MHC I-peptide complexes and use the vacuolar 
pathway but die within hours [122]. Liver sinusoidal 
endothelial cells express low levels of MHC II 
molecules but are unable to activate T lymphocytes 
[123]. Macrophages can engulf pathogens, form 
phagolysosomes can initiate proliferation and 
differentiation of CD8+T cells, but their effectiveness 
is restricted because of poor migratory properties 
[124]. Immature DCs phagocytose antigens and upon 
maturation present them complexed on MHC I 
molecules [120]. Mature DCs have the low endocytic 
capacity and express high levels of co-stimulatory 
molecules [120]. DCs suppress lysosomal proteases 
and inhibit lysosomal acidification via NADPH oxidase 
2-mediated alkalization of phagosomes and 
endosomes and thus maintain exogenous antigens for 
a long time ready for cross-presentation (delayed 
antigen degradation) [125]. Delayed antigen 
degradation allows antigens to move into the cytosol 
through channels such as SEC61 [126]. 
During the first step (antigen processing), two 
main tracks are – “available cytosolic” and “endocytic”, 
through which the exogenous peptides are degraded 
and loaded [113]. In the “cytosolic” track antigens are 
transported from endosomes to the cytosol for 
processing, loading in the ER, and transport of MHC I-
peptide complexes to the plasma membrane following 
the secretory pathway [30]. In the “endocytic” track 
processing (TAP-independent) and loading occur in 
the endosome, and MHC I molecules are recycled 
from the plasma membrane. The MHC I complex 
transported back to the plasma membrane from the 
endosome. TLRs induce MHC I molecules from the 
intracellular pool to phagosomes [30], [127].  
 
Figure 2: MHC class II antigen presentation 
 
The new understanding of cross-presentation 
has been built from data obtained from experiments in 
culture with Mo-DCs, GM-CSF cultures (GMDCs) and 
FTL3L-derived DC cultures [30]. The FTL3L-derived 
DCs in culture express RAB43, a molecule necessary 
for cross-presentation in in vivo cDC1s [128] and 
therefore are more suitable for studying cross-
presentation than GMDCs or Mo-DCs.  
In mice, the CD8α
+
 DCs (in lymphoid organs) 
are considered to be the dominant cross-presenting 
APC [129], but CD103+ DCs and inflammatory DCs 
are cross-presenters in certain conditions [130]. In 
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humans, one study shows superior cross-presentation 
of unstimulated CD141
+
 cDCs compared to CD1c
+
 
cDC and pDC [46]. Others report that unstimulated 
CD141
+
 cDCs are unable to cross-present [47]. 
Recent studies have revealed that, with the proper 
stimuli, all human DC subsets can cross-present in 
vitro [127]. However, CD141
+
 DCs are shown to be 
the most efficient cross-presenting subset following 
poly (I: C) stimulation, when using necrotic cell-
associated antigens [47], antigens delivered by Fcᵧ 
receptor targeting [3], or antigens delivered to 
endosomes / lysosomes [131]. The ability to cross-
present necrotic cell-derived antigens depends on the 
selective expression of ClEC9A on CD141
+
 DCs, a 
dead cell receptor that acts through delivery to both 
MHC class I and II [16], [47]. 
Haniffa et al., 2012 [48] tested the cross-
presentation ability of human skin (tissue) CD141
hi
 
DC, CD1c
+
 DC, CD14
+
 cells and epidermal LCs in 
comparison to CD141
+
 DCs, CD1c
+
 DCs, CD14
+
 
monocytes, and of (in vitro-derived) Mo-DCs and Mo-
LCs obtained from human blood. It has been 
established that in blood, only CD141
+
 DCs were able 
to cross-present efficiently, and require TLR3 
stimulation with poly (I: C) or exposure to a maturation 
cocktail (containing poly (I: C), LPS, IFNγ, IL1β, TNFα 
and IFNα). Mature Mo-DCs and Mo-LCs are also able 
to cross-present upon exposure to maturation cocktail 
but are refractory to TLR3 stimulus. In the skin, 
superior cross-presenting capacity has been found in 
CD141
hi
 DCs in the absence of stimulation, compared 
to all other DC subsets, including LCs. CD1c
+
 DCs 
show a little ability to cross-present [48]. 
In general, “resident” DCs are those in LN and 
other lymphoid organs and reside there during their 
entire life span. Moreover, the migratory DCs are that 
in peripheral tissues (NLT), they can capture antigen, 
mature, and migrate to draining LNs [33], [47]. In 
human axillary LNs there have been defined three 
subsets of blood-derived “resident” DCs namely, 
BDCA1
+
 DCs, Clec9A
+
 cDCs and BDCA4
+
 pDCs, and 
three subsets of skin-derived migratory DCs, namely 
LCs, CD1a
+
 DCs and CD14
+
 CD1a
-
 DCs [58]. It has 
been shown that resident DC subsets induce Th1 and 
Th2 polarisation and are powerful in cross-
presentation [58].  
In vivo cross-presentation occurs in 
secondary lymphoid organs, where resident CD1c
+
 
cDCs, CD141
+
 cDCs, and pDCs display equal cross-
presenting capacity [59]. Usually, antigens are 
captured by migratory cDC1s (CD8α+ DCs; CD141
+
 
cDC) or cDC2s (CD11b+; CD1c
+
 cDC) at the site of 
infection (NLT). Migratory cDCs migrate to regional 
LNs, where they can prime naïve CD4
+
 and CD8
+
 T 
cells through MHC: TCR contact. Migratory cDCs 
transfer antigen to resident cDC1s through cross-
dressing (see below). Resident cDC1s are helped 
through CD40 / CD40L from CD4+ T cells and can 
prime naïve CD8+ T cells via MHC I: TCR interaction 
[132]. 
 
Figure 3: Encountering of antigen at the site of infection; cross-
presentation occurring in secondary lymphoid organs; priming of 
naïve CD4+T-cells and CD8+ T-cells 
 
 MHC Class II Antigen Presentation 
 Professional APCs (mainly DCs and to a 
lesser extent, macrophages and B lymphocytes) 
express high levels of MHC class II molecules [16]. As 
opposed to macrophages, cDCs degrade the engulfed 
material slowly and in that way, preserve antigens for 
T cell recognition [50]. 
MHC class II molecules on DCs sample the 
extracellular matrix milieu and present exogenous 
antigens to CD4+ T-helper cells. For effective T-helper 
cell polarization already mature DCs express high 
levels of costimulatory molecules (CD80 / 86, CD40 / 
40L) and secrete cytokines such as IL12p70 and IL2 
(for Th1 immune responses), IL4 (for Th2 immune 
responses), IL23, IL6 and TGFβ (for Th17 immune 
responses) and TGFβ1, IL2 (for Treg responses) 
[125]. 
Similarly, to MHC class I molecules α and β 
chain of MHC class II molecules are synthesised in 
the endoplasmic reticulum and attached to the 
invariant chain (Ii or CD74) – (MHCII / Ii) [118]. Newly 
formed MHC class II molecules are delivered to the 
phagolysosome (late endosome) called MHCII 
compartment (MHCIIC). Bacterial or viral peptides, 
attached to TLRs are transported from the cellular 
surface to the late endosome via early endosome. 
TLR4 signalling by bacterial LPS triggers the efficient 
loading of MHC class II molecules with peptides [118]. 
In the late endosome-MHCIIC, the Ii is cleaved by the 
proteases (cathepsin S and L) and is replaced by the 
class II-associated peptide (CLIP). MHC class II 
molecules need a specific protein HLA-DM in humans 
to substitute CLIP for the antigenic peptide. Later 
CLIP is exchanged by the antigen, followed by 
vacuolar pathway transport of MHC II/antigen 
peptides to the plasma membrane to connect with 
TCR of CD4+ T cells [16], [118]. 
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Figure 4: Th-cell polarisation 
  
 
Antigen Presentation by pDCs 
 
The antigen-presentation by pDCs is similar 
but with a modulated efficiency and complementary to 
that of cDCs. The expression of MHC class I and 
class II and that of T cell co-stimulatory molecules on 
activated pDCs is lower as compared to cDCs, and 
therefore pDCs are less efficient at T-cell priming than 
cDCs [112]. It has also been shown that pDCs like 
cDCs can provoke T-cell tolerance via inducing Tregs 
[133]. 
Concerning MHC class II synthesis and 
viability, mature cDCs lose their ability to present via 
MHC II (because of inactivation of the promoter III – 
pIII) newly encountered antigens due to silencing of 
MHC presentation machinery. The master 
transcription factor responsible for MHC synthesis 
CIITA is down-regulated in mature cDCs [112]. 
Meanwhile, pIII, responsible for MHC II activation is 
activated in pDCs (non-silenced upon pDC activation) 
[110]. Therefore, pDCs are more efficient than cDCs 
in the presentation of endogenous antigens via MHC 
II [110], but the roles of both cDCs and pDCs in that 
process are complementary [110]. 
The differences in antigen presentation 
between cDCs and pDCs cannot be explained only by 
variability in MHC expression [112]. Several studies 
report that pDCs efficiently present endogenous 
antigens, constitutively expressed, degraded and 
attached to MHC I or II in the cytosolic or endosomal 
route similarly to cDCs [110], [134]. It is known that 
peptides degraded in the cytosol are presented on 
MHC I molecules (direct presentation), while peptides 
processed in the endocytic route (endogenous or 
exogenous) are presented on MHC II molecules [134].  
Nevertheless, pDCs can phagocytise 
exogenous antigens using specific receptors [110]. 
Such receptors are BDCA2, SIGLEC-H and DCIR 
[135] that mediate endocytosis, processing and 
presentation of exogenous antigens. These receptors 
induce a signalling cascade in pDCs inhibiting IFN I 
secretion [136]. Other receptors on pDCs are BST2 
(CD317 or HM1.24), PDCA1 [137] and FcRII (CD32) 
that mediate internalisation of immunoglobulins bound 
to integrin [112] and the tumour antigen NY-ESO-1 
[138]. 
 
Cross-presentation by pDCs 
Conceivably, the most efficient cross-
presenters are cDCs [119]. The cross-presenting 
capability of pDCs is controversial; for example, 
mouse pDCs do not possess cross-presenting 
capacity [137]. Some studies report that human pDCs 
can cross-present lipoproteins, cell-associated 
antigens or viral particles [16], [139]. The cross-
presenting capacity of human pDCs may be 
supported by still unknown receptors that capture 
exogenous antigens [112]. 
Recently, it was shown that there is another 
pathway of cross-presentation of tumour-associated 
antigen (TAA) – peptides complexed with MHC class I 
molecules to CD8
+
 CTLs, the process is called “cross-
dressing” [140]. The term cross-dressing means that 
peptide-MHC I complexes including TAAs belonging 
to neighbouring tumour cells, are transferred on the 
membrane of DCs [140], [141]. This process has been 
well documented for cDCs, but only recently was it 
shown that pDCs are very efficient in acquiring cell 
membrane patches from neighbouring cancer cells, 
and pDCs dressed with TAA-MHC I complexes are 
called drag cells. Tumor-specific CTLs efficiently 
recognize TAA-MHC I molecule complexes on pDCs 
[141]. 
Moreover, pDCs also secrete other pro-
inflammatory cytokines and chemokines, such as IL6, 
IL12, CXCL8, CXCL10, CCL3 and CCL4. pDCS can 
promote several processes: via IFNs and IL12 
promote CD8
+
 T-cells and Th1 immune responses; via 
TGFβ, IL6 idoleamine 2, 3-dioxygenase (IDO) and 
inducible co-stimulatory ligand (ICOSL) they drive 
Treg cell and Th17 immune responses; via IFNs, IL12 
and IL18 they promote the activation of NK cells. 
Expressed chemokines such as CCL3, CCL4, CXCL8 
and CXCL10 ensure immune cell recruitment, while 
the expression of MHC class I and II and of the co-
stimulatory molecules CD80, CD86 and CD40 enable 
pDCs to cross-prime CD8
+
 T cells as well as 
presenting antigen to CD4
+
 T-cells [18]. When pDCs 
are either unstimulated or activated by IDO, ICOSL, 
OX40L, programmed death-ligand (PD-L1) or 
granzyme B, they promote tolerance to tumour cells, 
alloantigens and harmless antigens [18], [142]. 
Human and mouse pDCs express cell surface 
receptors (TLR7 or TLR9) that control the production 
of IFN type I in response to the appropriate ligands 
(nucleic acids derived from viruses, bacteria and dead 
cells) [143].  
T-Cell Polarization 
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DCs have different phenotypes which alert 
their ability to polarise different Th subsets. Mature 
DCs produce cytokines, which induce differentiation of 
definite Th cell subsets that modify the immune 
response in the direction of effective or tolerogenic 
and immunosuppressive [144]. 
 DC1 phenotype (secreting IL12, IL15 and IFN 
type I) is named so because it induces the Th1 helper 
subset, which is responsible for immunity to 
intracellular pathogens [145], autoimmunity [145] and 
antitumor immunity. Th1 helpers secrete IFNγ and IL2 
by themselves and IL12 released by DC1s enhance 
antitumor immunity and activated NK cells [146].  
 DC2 phenotype during maturation leads to 
the secretion of IL1 which and they together with anti-
IFNγ, favours the production of Th2 cells. IL4 (not 
released by DCs, but by basophils and T-cells) [147] 
and IL10 also induced Th2 specialisation [148]. Th2 
immunity is directed against parasites and promotes 
allergic reactions [148]. Th2 cells secrete IL4, IL5, 
IL10, IL13 [125]. Two surface markers define DCs 
specialised in promoting Th2 cell responses. One 
marker is macrophage galactose-type C-type lectin 2 
(MGL2 / CD301b) and the second marker is PD-L2 
[149]. Th2 DCs express a specific transcription 
factors, IRF4 and STAT5, which regulate Th2 
differentiation [150], [151]. 
DC17s phenotype leads in the course of their 
maturation secretion IL6, TGFβ (released by stromal 
cells, macrophages etc.), IL21 and IL23 (inhibited by 
IL4 or IFNγ) and drive the generation of Th17 cells via 
IL-6, TGF-β and STAT3 pathway [150], [152]. Th17 
helper cells secrete high levels of IL-17, IL-21 and IL-
22 [125]. Their role in cancer is mainly maintenance of 
immunosuppression [153]. 
DC0 phenotype secreting IL10 and TGFβ 
(inhibited by IL6 and IL21) direct naïve T-cells into 
Treg differentiation [125].  
CD141
hi
 DCs are also the most active allo-
stimulators of CD4
+
 and CD8
+
 T-cells, as compared to 
CD1c
+
 and CD14
+
 DCs. Only CD141
hi
 DCs produce 
CXCL10 and TNFα after TLR3 stimulation but secrete 
little IL12 and IL23. No stimuli induce the secretion 
CXCL10 and TNF-α in CD1c
+
 and CD14
+
 DCs [48]. 
It has been reported that DCs activate CD4
+
 T 
cells via three signals: i) stimulation of TCR through 
MHC class II attached to an antigen-specific peptide 
complex; ii) co-stimulation meaning an interaction 
between co-stimulatory molecules on DCs (CD80 and 
CD86) with their ligands on T cells (CD28) and 
initiation of clonal expansion of TCR-stimulated T-
cells; iii) cytokines mainly provided by activated DCs 
that trigger polarization of naïve T-cells into effector T 
helper cells [148]. Upon stimulation by exogenous 
pathogens, allergens, or endogenous inflammatory 
signals, DCs produce various types of cytokines such 
as IL1, IL6, IL12, IL21, IL23, IL27, and TNFα 
functioning as signal 3 [154]. Cytokines trigger the 
type of STAT activation in T cells that is crucial in 
determining the effector lineages of T helper cells via 
inducing distinct transcription factors. In other words, 
distinct cytokines are required for the commitment of T 
cells to each T helper lineage.  
 
 
Dendritic Cells and Cancer 
 
DCs play a key role in the regulation of 
tumour-specific immune responses [155]. Different DC 
subsets in cancer can exert an effective anti-tumor 
immune response, since immature DCs capture 
tumor-specific antigens, while immunogenic or mature 
DCs up-regulate MHC and co-stimulatory molecules 
(CD80, CD83, CD86, CD40), secrete high levels of 
bioactive IL12p70, skewing and prime CD8
+
 T cell 
responses (CTLs), skewing the response to Th1 and 
induce optimal anti-tumor immunity [156], [157].  
Tolerogenic DCs have a role in maintaining 
immunosuppression in tumour [155]. Tumor-infiltrating 
DCs are immature with down-regulation of co-
stimulatory molecules, secretion of IL-10 and 
induction of Th2 immune responses and Treg 
expansion in the tumour milieu [156], [158]. Tumour 
cells impair DCs function through the secretion of 
immunosuppressive molecules such as IL10, TGFβ 
and PGE2 [158], or VEGF, which inhibit DCs 
maturation and their ability to activate T cells [157]. 
Tumours produce elevated levels of CCL22 
chemokine and ICOSL, molecules that attract DCs 
[159] and increase the expression of CTLA4 and PD1 
/ PD-L1, co-stimulatory molecules that can suppress T 
cell proliferation and activity in cancer [159], [160].  
In human tumor tissue four DC subsets are 
found namely pDCs and mDCs including CD16
+
 DCs, 
BDCA1
+
 DCs, and BDCA3
+
 DCs [155]. The tumour 
microenvironment inhibits immunogenic Mo-DCs 
through secretion of IL-10 and IL6 cytokines, and 
parallelly promote monocyte maturation into 
macrophages [161], [162]. Tumor-infiltrating DCs are 
shown to be immunogenic at early stages of cancer 
development and convert to immunosuppressive 
types (MHC II
low
, CD40
low
 and PD-L1
high
) at advanced 
tumour stages. Moreover, immunostimulatory cDCs 
can transform into regulatory macrophage-like cells 
that suppress T-cell responses through nitric oxide, 
arginase activity and IL10 [163]. 
 
pDCs and tumour microenvironment 
Immature myeloid DCs and pDCs [164] 
accumulate in human tumors and in peripheral blood 
[159] and predict poor prognosis for specific cancer 
types. In the tumour microenvironment, pDCs are 
non-activated (immature) that don’t produce IFN type I 
Gulubova et al. Myeloid and Plasmacytoid Dendritic Cells and Cancer – New Insights 
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and lack the expression of co-stimulatory molecules 
[165], [166]. Tumor-infiltrating pDCs produce IDO that 
promotes Treg activation and immunosuppression in 
tumours [167]. Tumour pDCs express high levels of 
ICOS-L and in that way stimulate ICOS+ Tregs 
(ICOS+ FoxP3+ Tregs) [168]. 
Also, pDCs after activation can undergo 
important phenotypic changes towards mDC 
phenotype and induce IFN I production that amplifies 
the release of IL12p70 from mDCs and NK cells [169]. 
Interestingly, pDCs can promote Th2-like immune 
responses, since increased IFNα stimulate the change 
of pDCs into Th1-inducing pDCs, while the absence of 
IFNα leads to Th2-inducing pDCs [169]. It was shown 
that pDCs expressed on their surface CD56, PD-L1, 
granzyme B and the TNF-related apoptosis-inducing 
ligand (TRAIL) [170]. The pDCs tumour cell killing is 
dependent strictly on TRAIL-associated apoptosis.  
DCs have the capacity of the direct cytotoxic 
killing of tumour cells together with CD8
+
 CTLs, NK 
cells, and γ/δ T-cells) [170]. TpDC cytotoxicity was 
granzyme dependent [167], [171]. 
In conclusion, we may state that human DCs 
are the main immune cells that orchestrate the 
immune response in the tumour microenvironment 
and represent the most hopeful tool for future DC 
vaccines that are an alternative of check-point 
inhibitors for tumour immunotherapy. 
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